Literature DB >> 9185591

Analysis of an interaction between the soluble vaccinia virus-coded type I interferon (IFN)-receptor and human IFN-alpha1 and IFN-alpha2.

H Liptáková1, E Kontseková, A Alcamí, G L Smith, P Kontsek.   

Abstract

The soluble B18R protein coded by vaccinia virus exerts properties of a type I interferon (IFN)-receptor with broad species specificity. We analyzed neutralizing and binding activity of the B18R protein against several recombinant human type I IFNs. The B18R protein inhibited the antiviral potency of IFN-alpha1, IFN-alpha2, IFN-alpha8/1/8, and IFN-omega on human cells. The N-terminal domain of human type I IFN is involved in the high affinity binding to its cellular receptor. To localize the binding domain(s) of IFN with the B18R protein, competition experiments between B18R, and mapped monoclonal antibodies to IFN-alpha1 and IFN-alpha2 were performed. Surprisingly, our data indicated that the contact area between the B18R protein and IFN comprised in addition to the N-terminal region of IFN-molecule also its C-terminal portion. We suggest that this different pattern of interaction with a ligand might determine the ability of B18R protein to bind type I IFNs of different species.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9185591     DOI: 10.1006/viro.1997.8527

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  16 in total

Review 1.  Initiation of primary anti-vaccinia virus immunity in vivo.

Authors:  Matthew A Fischer; Christopher C Norbury
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

2.  The recombinant vaccinia virus gene product, B18R, neutralizes interferon alpha and alleviates histopathological complications in an HIV encephalitis mouse model.

Authors:  Cari Fritz-French; Ramzi Shawahna; Jennifer E Ward; Leonard E Maroun; William R Tyor
Journal:  J Interferon Cytokine Res       Date:  2014-02-24       Impact factor: 2.607

3.  Vaccinia virus blocks gamma interferon signal transduction: viral VH1 phosphatase reverses Stat1 activation.

Authors:  P Najarro; P Traktman; J A Lewis
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

4.  HIV downregulates interferon-stimulated genes in primary macrophages.

Authors:  Seong-Heon Wie; Pinyi Du; Tiffany Q Luong; Steffney E Rought; Nadejda Beliakova-Bethell; Jean Lozach; Jacques Corbeil; Richard S Kornbluth; Douglas D Richman; Christopher H Woelk
Journal:  J Interferon Cytokine Res       Date:  2012-12-31       Impact factor: 2.607

5.  The vaccinia virus soluble alpha/beta interferon (IFN) receptor binds to the cell surface and protects cells from the antiviral effects of IFN.

Authors:  A Alcamí; J A Symons; G L Smith
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Reprogramming human fibroblasts to pluripotency using modified mRNA.

Authors:  Pankaj K Mandal; Derrick J Rossi
Journal:  Nat Protoc       Date:  2013-02-21       Impact factor: 13.491

7.  Association of IRF5 polymorphisms with activation of the interferon alpha pathway.

Authors:  Ornella J Rullo; Jennifer M P Woo; Hui Wu; Alice D C Hoftman; Paul Maranian; Brittany A Brahn; Deborah McCurdy; Rita M Cantor; Betty P Tsao
Journal:  Ann Rheum Dis       Date:  2009-10-23       Impact factor: 19.103

8.  Evolution of the interferon alpha gene family in eutherian mammals.

Authors:  Christopher H Woelk; Simon D W Frost; Douglas D Richman; Prentice E Higley; Sergei L Kosakovsky Pond
Journal:  Gene       Date:  2007-04-03       Impact factor: 3.688

9.  Inhibition of type I and type III interferons by a secreted glycoprotein from Yaba-like disease virus.

Authors:  Jiaying Huang; Sergey V Smirnov; Anita Lewis-Antes; Murugabaskar Balan; Wei Li; Sheila Tang; Gemma V Silke; Mike M Pütz; Geoffrey L Smith; Sergei V Kotenko
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-21       Impact factor: 11.205

Review 10.  Modulation of the host immune response by cowpox virus.

Authors:  Dina Alzhanova; Klaus Früh
Journal:  Microbes Infect       Date:  2010-07-29       Impact factor: 2.700

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.